The current status of drug development of hypoxic cell radiosensitizers and their potential role in gynecologic oncology
Both laboratory and clinical data suggest that hypoxia contributes to the failure of radiotherapy to achieve local control of bulky gynecologic tumors. As part of a Phase I trial of hypoxic cell radiosensitizers, 19 women at Stanford University with advanced (n . 6) or recurrent (n . 13) pelvic neoplasms were treated with radiotherapy plus desmethylmisonidazole. Complete or partial response occurred in 42% of patients with some patients achieving local control for over 1 year. It is unknown if the sensitizer added to the results of radiotherapy alone. A Phase I trial of a theoretically superior sensitizer, SR-2508, is soon to begin. It is anticipated that the dose-limiting neurotoxicity seen with misonidazole and desmethylmisonidazole will either be eliminated or will occur at a much higher total dose of drug. Many patients with gynecologic tumors could potentially benefit from participation in the new drug trials.
- Research Organization:
- Department of Radiology, Stanford University Medical Center, California
- OSTI ID:
- 6783123
- Journal Information:
- Gynecol. Oncol.; (United States), Vol. 18:1
- Country of Publication:
- United States
- Language:
- English
Similar Records
A comparison of the cytological effects of three hypoxic cell radiosensitizers
Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice
Related Subjects
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
FEMALE GENITALS
NEOPLASMS
CHEMOTHERAPY
RADIOSENSITIZERS
COMPARATIVE EVALUATIONS
FEMALES
MISONIDAZOLE
PATIENTS
RADIOTHERAPY
ANTINEOPLASTIC DRUGS
AZOLES
BODY
DISEASES
DRUGS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
MEDICINE
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
RADIOLOGY
THERAPY
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)
560306 - Chemicals Metabolism & Toxicology- Man- (-1987)